Lysaker, Norway—Researchers from Maastricht University in the Netherlands have released some preliminary results from a recent trial on a branded natural vitamin K2 ingredient (MenaQ7 from NattoPharma, based here).

The team collected data from 244 postmenopausal women from 2008 through 2011. During the three-year trial, the women took a low dose of the vitamin (180 mcg) or a placebo to see whether they affected bone and heart health.

With regard to bone density, researchers found that bone mass and quality was better preserved in the vitamin K2 group. The vitamin also had positive effects on cardiovascular disease indicators. According to a press statement, “Among several findings the pulse wave velocity parameter improved significantly by MenaQ7 treatment.”

The final analysis of these data is expected to be published later this year.

Published in WholeFoods Magazine, March 2012 (online 1/19/12)